Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: European Journal of Cancer, 151, S. 3-13
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2021
- Event
-
Veröffentlichung
- (who)
-
Elsevier BV
- (when)
-
2021
- Creator
-
Riedl, Jakob M.
Posch, Florian
Horvath, Lena
Gantschnigg, Antonia
Renneberg, Felix
Schwarzenbacher, Esther
Moik, Florian
Barth, Dominik A.
Rossmann, Christopher H.
Stotz, Michael
Schaberl-Moser, Renate
Pichler, Martin
Stöger, Herbert
Greil, Richard
Djanani, Angela
Schlick, Konstantin
Gerger, Armin
- DOI
-
10.1016/j.ejca.2021.03.040
- URN
-
urn:nbn:de:bvb:384-opus4-1016393
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Riedl, Jakob M.
- Posch, Florian
- Horvath, Lena
- Gantschnigg, Antonia
- Renneberg, Felix
- Schwarzenbacher, Esther
- Moik, Florian
- Barth, Dominik A.
- Rossmann, Christopher H.
- Stotz, Michael
- Schaberl-Moser, Renate
- Pichler, Martin
- Stöger, Herbert
- Greil, Richard
- Djanani, Angela
- Schlick, Konstantin
- Gerger, Armin
- Universität Augsburg
- Elsevier BV
Time of origin
- 2021
Other Objects (12)
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Best of ASCO 2022: bladder cancer
Pankreaskarzinom nab-Paclitaxel
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Breast cancer nab-Paclitaxel
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Best of ASCO 2022: bladder cancer
Pankreaskarzinom nab-Paclitaxel
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Breast cancer nab-Paclitaxel
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Best of ASCO 2022: bladder cancer
Pankreaskarzinom nab-Paclitaxel
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Breast cancer nab-Paclitaxel
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients